Status:
COMPLETED
Study of Luteinizing Hormone-Releasing Hormone Analog (LHRHa) in Pubertal Patients With Extreme Short Stature
Lead Sponsor:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Conditions:
Dwarfism
Growth Disorder
Eligibility:
All Genders
Phase:
PHASE2
Brief Summary
Children with extreme short stature (height) and their families often experience significant psychological stress related to concerns about adult height. In addition, short stature often results in li...
Detailed Description
Children with extreme short stature and their families frequently experience significant psychological stress related to concerns about adult height. Additionally, extreme short stature often presents...
Eligibility Criteria
Patients with extreme short stature will qualify for inclusion under this protocol if they meet the following criteria:
Age 9 through 15.99 years at the start of treatment.
Tanner II-V pubertal development.
Height at least 2.25 S.D. below the median for chronologic age at the time of pubertal onset, or a predicted adult height at least 2.25 S.D. below median adult height.
The height criterion must be met before study entry, but not necessarily on the actual date the patient starts to take the protocol injections because advancing puberty may cause an increase in height velocity that temporarily increases height standard deviation score.
Unfused carpal and phalangeal epiphyses by bone age x-ray.
Key Trial Info
Start Date :
November 1 1983
Trial Type :
INTERVENTIONAL
End Date :
October 1 2001
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00001190
Start Date
November 1 1983
End Date
October 1 2001
Last Update
March 4 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Institute of Child Health and Human Development (NICHD)
Bethesda, Maryland, United States, 20892